Вопросы современной педиатрии (Dec 2014)

USE OF ETANERCEPT IN PATIENTS WITH OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS

  • Т. М. Bzarova,
  • Ye. I. Alekseeva,
  • О. L. Lomakina,
  • K. B. Isaeva,
  • S. I. Valieva,
  • R. V. Denisova,
  • Т. V. Sleptsova

DOI
https://doi.org/10.15690/vsp.v13i6.1206
Journal volume & issue
Vol. 13, no. 6
pp. 72 – 77

Abstract

Read online

The article describes a case of torpid course of oligoarticular juvenile idiopathic arthritis (JIA) and the successful use of soluble receptorsf or tumor necrosis factor alpha (TNF) — etanercept — during its treatment. After 4 weeks of treatment the patient returned to normal laboratory indices of the disease activity, and the duration of morning stiffness and severity of inflammatory changes in the joints decreased; after 3 months the acute inflammatory changes in the joints disappeared; after 6 months the patient's functional ability restored; and after 9 months the medically induced remission of the disease was recorded.

Keywords